Millions Of Americans Are Losing Weight With GLP-1s. Here’s How That’s Changing Retail.

The increasing use of GLP-1 drugs by American consumers is creating a significant new opportunity for the apparel industry, potentially boosting clothing sales by up to $13 billion annually. Millions of Americans are experiencing substantial body size changes due to these medications, leading to shifts in purchasing patterns. Retail experts are observing early indicators of this trend, such as a decline in sales of larger bra sizes. Personal styling service Stitch Fix has noted an increase in customers citing weight loss as their reason for buying new clothes. Individuals on GLP-1s often drop multiple sizes, and some are motivated to purchase tailored or tighter-fitting attire to showcase their new physique. This weight loss can also foster new confidence, encouraging shoppers to buy new dresses or update their overall look. Online communities dedicated to GLP-1 users frequently feature before-and-after photos, highlighting the potential impact on the apparel sector. Estimates suggest that if current GLP-1 users each drop three sizes and purchase 5 to 8 clothing items this year, it could result in 150 million to 700 million apparel items sold, translating to $3 billion to $13 billion in sales. The number of GLP-1 users is projected to grow, especially with the availability of pill forms and decreasing prices. JP Morgan predicts over 30 million Americans could be on GLP-1 treatments by 2030. However, these projections are based on assumptions of rapid and widespread adoption, which may be exaggerated. The high cost of GLP-1 drugs, often exceeding $1,000 per month without insurance, could limit discretionary spending on new clothing for some users. Some individuals might opt to wear existing smaller-sized clothes or purchase versatile items that accommodate multiple sizes. Despite these potential limitations, retailers are hopeful that this trend will provide a much-needed lift to apparel sales, which are otherwise expected to grow minimally. Experts anticipate the GLP-1 market will continue to expand in the near future.